Summary
Updated Aug 31, 2026
GOLDMAN SACHS GROUP INC files SEC Form 4 reports at Attovia Therapeutics, Inc. (ATTO). 10 SEC Form 4 filings on record going back to 2024, most recently on 28 August 2026. Most recent open-market trade: bought $8.50M of ATTO on 28 August 2026. Lifetime open-market purchases: $26.26M. Lifetime open-market sales: $19.57M. Historical track record: 5/5 stars across 50 tracked purchases.
Recent Transactions
20Every recent SEC Form 4 transaction GOLDMAN SACHS GROUP INC has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★★★ (5/5) |
| Total purchases tracked | 50 |
| Purchases with forward-return data | 30 |
| 30-day win rate | 100% |
| 90-day win rate | 100% |
| Avg 5-day return | +0.88% |
| Avg 30-day return | +20.74% |
| Avg 90-day return | +41.48% |
| Best 30-day return | +20.74% |
Trading Pattern
InsiderAlpha's records for GOLDMAN SACHS GROUP INC go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. The typical open-market purchase is $438K (60 buys totaling $26.26M). The largest single buy on record is $8.50M of ATTO in 2026. Sales side: 73 recorded sales totaling $19.57M, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies GOLDMAN SACHS GROUP INC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Colin Walsh - $27.32M of ATTO open-market activity in the last 12 months
- Redmile Group, LLC - $10.20M of ATTO open-market activity in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M of ATTO open-market activity in the last 12 months
- venBio Global Strategic Fund IV, L.P. - $6.50M of ATTO open-market activity in the last 12 months
- Sanofi - $5.10M of ATTO open-market activity in the last 12 months
- Aperture Sponsor LLC - $2.23M of APUR open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
What is GOLDMAN SACHS GROUP INC?
GOLDMAN SACHS GROUP INC is a corporate entity of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 10 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has GOLDMAN SACHS GROUP INC submitted recently?
4 primary Form 4 filings in the last 90 days, covering 3 companies.
Has GOLDMAN SACHS GROUP INC been buying or selling stock?
Recorded transactions: 60 open-market purchases ($26.26M) and 73 open-market sales ($19.57M) across all tracked filings.
How accurate is GOLDMAN SACHS GROUP INC's historical track record?
Across 50 tracked purchases, GOLDMAN SACHS GROUP INC averaged +20.7% avg 30-day return with a 100% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
Where can I see all of GOLDMAN SACHS GROUP INC's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow GOLDMAN SACHS GROUP INC and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial